MX354653B - Métodos para tratamiento de enfermedades y trastornos relacionados con la actividad de la proteína 1 similar a transducina b (tbl1), que incluyen la neoplasia mieloproliferativa y la leucemia mieloide crónica. - Google Patents
Métodos para tratamiento de enfermedades y trastornos relacionados con la actividad de la proteína 1 similar a transducina b (tbl1), que incluyen la neoplasia mieloproliferativa y la leucemia mieloide crónica.Info
- Publication number
- MX354653B MX354653B MX2014005498A MX2014005498A MX354653B MX 354653 B MX354653 B MX 354653B MX 2014005498 A MX2014005498 A MX 2014005498A MX 2014005498 A MX2014005498 A MX 2014005498A MX 354653 B MX354653 B MX 354653B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- myeloid leukemia
- protein
- transducin
- beta
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
Abstract
La presente invención describe la utilización del compuesto de dioxima de antraceno-9,10-diona: dioxima de 2-((3R,5S)-3,5-dimetil piperdin-iIsulfonilo)-7-((3S, 5R)-3,5-dimetilpiperidin- 1- ilsulfonil)antraceno-9,10-diona para el tratamiento del cáncer, que incluye neoplasia mieloproliferativa, leucemia mieloide crónica y leucemia mieloide aguda. Tal compuesto de dioxima de antraceno-9,10-diona interrumpe la ruta de Wnt/beta-catenina e inhibe la actividad desregularizada de esta ruta para el tratamiento, la diagnosis y la prevención de los trastornos relacionados con la ruta de beta-catenina, así como interfiere en la interacción de la proteína 1 similar a la transducina beta (TBL1, por sus siglas en inglés) con la molecula coactivadora. beta-canina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161556245P | 2011-11-06 | 2011-11-06 | |
PCT/US2012/063746 WO2013067547A1 (en) | 2011-11-06 | 2012-11-06 | METHODS FOR TREATMENT OF DISEASES AND DISORDERS RELATED TO TRANSDUCIN β-LIKE PROTEIN 1 (TBL 1) ACTIVITY, INCLUDING MYELOPROLIFERATIVE NEOPLASIA AND CHRONIC MYELOID LEUKEMIA |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014005498A MX2014005498A (es) | 2016-05-05 |
MX354653B true MX354653B (es) | 2018-03-07 |
Family
ID=48192926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014005498A MX354653B (es) | 2011-11-06 | 2012-11-06 | Métodos para tratamiento de enfermedades y trastornos relacionados con la actividad de la proteína 1 similar a transducina b (tbl1), que incluyen la neoplasia mieloproliferativa y la leucemia mieloide crónica. |
Country Status (16)
Country | Link |
---|---|
US (1) | US9238030B2 (es) |
EP (1) | EP2773607B1 (es) |
JP (1) | JP6063472B2 (es) |
KR (1) | KR102336767B1 (es) |
CN (1) | CN103917514B (es) |
AU (1) | AU2012332111B2 (es) |
BR (1) | BR112014010584A2 (es) |
CA (1) | CA2853491C (es) |
EA (1) | EA027770B1 (es) |
ES (1) | ES2624427T3 (es) |
HK (1) | HK1198440A1 (es) |
IL (1) | IL232452A (es) |
MX (1) | MX354653B (es) |
SG (1) | SG11201402056XA (es) |
WO (1) | WO2013067547A1 (es) |
ZA (1) | ZA201403003B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9963475B2 (en) * | 2015-07-28 | 2018-05-08 | Beta Cat Pharmaceuticals, Inc. | Anthracene-9, 10-dione dioxime compound prodrugs and their uses |
US9725473B2 (en) * | 2015-07-28 | 2017-08-08 | Beta Cat Pharmaceuticals, Inc. | Anthracene-9, 10-dione dioxime compound prodrugs and their uses |
WO2018223023A1 (en) | 2017-06-02 | 2018-12-06 | Beta Cat Pharmaceuticals, Inc. | Methods for treatment of fibrotic diseases |
WO2019099836A1 (en) * | 2017-11-16 | 2019-05-23 | Northwestern University | Inhaled formulation of a molecular inhibitor of wnt/beta-catenin signaling for treating interstitial lung diseases |
WO2019229001A1 (en) * | 2018-05-30 | 2019-12-05 | Otto-Von-Guericke-Universität Magdeburg | Compounds for the treatment of jak2-v617f-associated cmn |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2871493C (en) * | 2007-05-10 | 2017-03-28 | Dogwood Pharmaceuticals, Inc. | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof |
US8304408B2 (en) * | 2007-05-24 | 2012-11-06 | The Regents Of The University Of California | Wnt signaling inhibitors, and methods for making and using them |
EA030302B1 (ru) * | 2008-11-21 | 2018-07-31 | Форест Лэборетериз Холдингз Лимитед | Антрахинондиоксимы и их применение |
WO2011019648A1 (en) * | 2009-08-10 | 2011-02-17 | Epitherix, Llc | Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof |
EP2470534A4 (en) * | 2009-08-24 | 2013-02-27 | Merck Sharp & Dohme | INHIBITION OF JAK BLOCKES TOXICITIES ASSOCIATED WITH INTERFERENCE RNA |
CA2775155A1 (en) * | 2009-10-01 | 2011-04-07 | Csl Limited | Method of treatment of philadelphia chromosome positive leukemia |
-
2012
- 2012-11-06 WO PCT/US2012/063746 patent/WO2013067547A1/en active Application Filing
- 2012-11-06 KR KR1020147015141A patent/KR102336767B1/ko not_active Application Discontinuation
- 2012-11-06 ES ES12845590.4T patent/ES2624427T3/es active Active
- 2012-11-06 BR BR112014010584A patent/BR112014010584A2/pt not_active IP Right Cessation
- 2012-11-06 SG SG11201402056XA patent/SG11201402056XA/en unknown
- 2012-11-06 EP EP12845590.4A patent/EP2773607B1/en active Active
- 2012-11-06 JP JP2014540200A patent/JP6063472B2/ja active Active
- 2012-11-06 MX MX2014005498A patent/MX354653B/es active IP Right Grant
- 2012-11-06 EA EA201490937A patent/EA027770B1/ru not_active IP Right Cessation
- 2012-11-06 AU AU2012332111A patent/AU2012332111B2/en active Active
- 2012-11-06 CA CA2853491A patent/CA2853491C/en active Active
- 2012-11-06 US US13/670,377 patent/US9238030B2/en active Active
- 2012-11-06 CN CN201280054386.3A patent/CN103917514B/zh active Active
-
2014
- 2014-04-24 ZA ZA2014/03003A patent/ZA201403003B/en unknown
- 2014-05-04 IL IL232452A patent/IL232452A/en active IP Right Grant
- 2014-11-26 HK HK14111950A patent/HK1198440A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
IL232452A (en) | 2017-01-31 |
EP2773607A4 (en) | 2015-03-11 |
AU2012332111A1 (en) | 2014-05-22 |
WO2013067547A1 (en) | 2013-05-10 |
CN103917514A (zh) | 2014-07-09 |
CA2853491A1 (en) | 2013-05-10 |
IL232452A0 (en) | 2014-06-30 |
MX2014005498A (es) | 2016-05-05 |
ZA201403003B (en) | 2017-08-30 |
ES2624427T3 (es) | 2017-07-14 |
NZ624446A (en) | 2016-01-29 |
JP6063472B2 (ja) | 2017-01-18 |
EP2773607B1 (en) | 2017-03-29 |
BR112014010584A2 (pt) | 2017-05-02 |
CA2853491C (en) | 2019-12-10 |
KR20140089418A (ko) | 2014-07-14 |
US9238030B2 (en) | 2016-01-19 |
KR102336767B1 (ko) | 2021-12-10 |
EA027770B1 (ru) | 2017-08-31 |
SG11201402056XA (en) | 2014-10-30 |
CN103917514B (zh) | 2016-11-16 |
AU2012332111B2 (en) | 2016-11-17 |
JP2014534229A (ja) | 2014-12-18 |
EA201490937A1 (ru) | 2014-08-29 |
HK1198440A1 (en) | 2015-04-24 |
EP2773607A1 (en) | 2014-09-10 |
US20130143920A1 (en) | 2013-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201591753A1 (ru) | 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh | |
EA201490272A1 (ru) | Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы | |
EA202190619A1 (ru) | Противовирусные соединения | |
CO6480975A2 (es) | Mimetico de smac | |
GEP20166438B (en) | Imidazopyrrolidinone compounds | |
EA201591745A1 (ru) | 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантого idh | |
EA201490420A1 (ru) | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С α-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ | |
BR112014013526A8 (pt) | conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados | |
MX343561B (es) | Compuestos de imidazolpiridazina. | |
MX2014005498A (es) | Metodos para tratamiento de enfermedades y trastornos relacionados con la actividad de la proteina 1 similar a transducina b (tbl1), que inlcuyen la neoplasia mieloproliferativa y la leucemia mieloide cronica. | |
CU24265B1 (es) | Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, útiles en el tratamiento del cáncer | |
MA37866A1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
EA201070618A1 (ru) | 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus | |
EA201491391A1 (ru) | Терапевтически активные соединения и способы их применения | |
EA201290844A1 (ru) | Соединения для ингибирования иммунопротеасом | |
UA113062C2 (xx) | Похідні 5-фтор-4-іміно-3-(заміщеного)-3,4-дигідропіримідин-2(1h)ону | |
EA201500574A1 (ru) | Новые инданилоксидигидробензофуранилуксусные кислоты | |
EA201300388A1 (ru) | Соединения замещенного бензамида | |
EA201490423A1 (ru) | СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА | |
TN2014000112A1 (en) | Ep1 receptor ligands | |
EA201590562A1 (ru) | Бензамиды | |
EA201301114A1 (ru) | Ингибитор фосфоинозитид-3-киназы, содержащий цинксвязывающий фрагмент | |
MX2013011124A (es) | Compuestos para el tratamiento del sindrome metabolico. | |
MA38645B1 (fr) | Nouveaux inhibiteurs de cyp17/antiandrogènes | |
EA201501187A1 (ru) | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |